Degradation of radioiodinated B cell monoclonal antibodies: Inhibition via a FCγ-receptor-II-mediated mechanism and by drugs

Cancer Immunology, Immunotherapy

Volumn 42, Issue 1, 1996, Pages 24-30

  Vervoordeldonk, Susan F ^a   Balkenende, Astrid Y ^a   Van Den Berg, Henk ^b   Von Dem Borne, Albert E G Kr ^c   Van Der Schoot, C Ellen ^a,c   Van Leeuwen, Eleonore F ^b   Slaper Cortenbach, Ineke C M ^a,d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b EMMA CHILDREN S HOSPITAL   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d CENTRAL LABORATORY   (Netherlands)

Author keywords

B cell malignancies; Degradation; Fc receptor; Monoclonal antibody; Radioimmunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CD19 ANTIBODY; CD20 ANTIBODY; CD22 ANTIBODY; CHLOROQUINE; COLCHICINE; ETOPOSIDE; FC RECEPTOR; IODINE 125; MONENSIN; PACLITAXEL; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE; B LYMPHOCYTE ANTIGEN; CALCIUM CHANNEL BLOCKING AGENT; CD19 ANTIGEN; CD22 ANTIGEN; CD22 PROTEIN, HUMAN; CD22 PROTEIN, MOUSE; CELL ADHESION MOLECULE; DIAGNOSTIC AGENT; IMMUNOGLOBULIN CLASS; IMMUNOTOXIN; LECTIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE;

ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; CATABOLISM; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; ANIMAL; B LYMPHOCYTE; BURKITT LYMPHOMA; COMPARATIVE STUDY; DRUG EFFECT; IMMUNOLOGY; METABOLISM; MOUSE; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; BIOLOGICAL TRANSPORT; BURKITT LYMPHOMA; CALCIUM CHANNEL BLOCKERS; CELL ADHESION MOLECULES; CHLOROQUINE; COLCHICINE; ETOPOSIDE; HUMANS; IMMUNOGLOBULIN ISOTYPES; IMMUNOTOXINS; IODINE RADIOISOTOPES; LECTINS; LEUKEMIA, B-CELL; MICE; MONENSIN; PACLITAXEL; RADIOIMMUNOTHERAPY; RECEPTORS, IGG; VERAPAMIL; VINBLASTINE; VINCRISTINE;

EID: 0029664988     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050247     Document Type: Article

References (49)

1. Appelbaum FR, Matthews DC, Eary JF, Badger CC, Kellogg M, Press OW, Martin PJ, Fisher DR, Nelp WB, Thomas ED, et al (1992) The use of radiolabeled ant-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 54: 829
2. Beishuizen A, Hahlen K, Hagemeijer A, Verhoeven MA, Hooijkaas H, Adriaansen HJ, Wolvers Tettero IL, Werin ER van, Dongen JJ van (1991) Multiple rearranged immunoglobulin genes in childhood acute lymphoblastic leukemia of precursor B-cell origin. Leukemia 5: 657
3. Candiani C, Franceschi A, Chignola R, Pasti M, Anselmi C, Benoni G, Tridente G, Colombatti M (1992) Blocking effect of human serum but not of cerebrospinal fluid on ricin A chain immunotoxin potentiation by monensin or carrier protein-monensin conjugates. Cancer Res 52: 623
4. Caron PC, Jurcic JG, Scott AM, Finn RD, Divgi CR, Graham MC, Jureidini IM, Sgouros G, Tyson D, Old LJ, et al (1994) A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood 83: 1760
5. Dollery C (1991) Vinblastine. Therapeutic drugs. Churchill Livingstone, Edinburgh London Melbourne, p V27
6. Dollery C (1991) Chloroquine. Therapeutic drugs. Churchill Livingstone, Edinburgh London Melbourne, p C189
7. Dollery C (1991) Vincristine. Therapeutic drugs. Churchill Livingstone, Edinburgh London Melbourne, p V31
8. Demignot S, Pimm MV, Thorpe SR, Baldwin RW (1991) Differences between the catabolism and tumour distribution of intact monoclonal antibody (791T/36) and its Fac/c fragment in mice with tumour xenografts revealed by the use of a residualizing radiolabel (dilactitol-125I-tyramine) and autoradiography. Cancer Immunol Immunother 33: 359
9. Geissler F, Anderson SK, Press O (1991) Intracellular catabolism of radiolabeled anti-CD3 antibodies by leukemic T cells. Cell Immunol 137: 96
10. Geissler F, Anderson SK, Venkatesan P, Press O (1992) Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells. Cancer Res 52: 2907
11. Gelmon K (1994) The taxoids: paclitaxel and docetaxel. Lancet 344: 1267
12. Greenman J, Tutt AL, George AJ, Pulford KA, Stevenson GT, Glennie MJ (1991) Characterization of a new monoclonal anti-Fc gamma RII antibody, AT10, and its incorporation into a bispecific F(ab′)2 derivative for recruitment of cytotoxic effectors. Mol Immunol 28: 1243
13. Huizing MT, Keung AC, Rosing H, Kuij V van der, Bokkel Huinink WW ten, Mandjes IM, Dubbelman AC, Pinedo HM, Beijnen JH (1993) Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11: 2127
14. Jaffrezou JP, Levade T, Thurneyssen O, Chiron M, Bordier C, Attal M, Chatelain P, Laurent G (1992) In vitro and in vivo enhancement of ricin-A chain immunotoxin activity by novel indolizine calcium channel blockers: delayed intracellular degradation linked to lipidosis induction. Cancer Res 52: 1352
15. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, et al (1993) Radioimmunotherapy of B-cell lymphoma withanti-B1 (anti-CD20) antibody. N Engl J Med 329: 459
16. Kurlander RJ (1983) Blockade of Fc receptor-mediated binding to U-937 cells by murine monoclonal antibodies directed against a variety of surface antigens. J Immunol 131: 140
17. Kyriakos RJ, Shih LB, Ong GL, Patel K, Goldenberg DM, Mattes MJ (1992) The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res 52: 835
18. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72: 77
19. Manske JM, Buchsbaum DJ, Vallera DA (1989) The role of ricin B chain in the intracellular trafficking of anti-CD5 immunotoxins. J Immunol 142: 1755
20. Mattes MJ, Griffiths GL, Diril H, Goldenberg DM, Ong GL, Shih LB (1994) Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer 73: 787
21. 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 85: 1122
22. Matzku S, Moldenhauer G, Kalthoff H, Canevari S, Colnaghi M, Schuhmacher J, Bihl H (1990) Antibody transport and internalization into tumours. Br J Cancer [Suppl] 10: 1
23. Mross K, Bewermeier P, Reifke J, Kruger W, Stockschlader M, Zander A, Hossfeld DK (1994) Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusion. Bone Marrow Transplant 13: 423
24. 125I radiolabeled T101 anti-CD5 monoclonal antibody. Int J Radiat Appl Instrum [B] 17: 201
25. Novak Hofer I, Amstutz HP, Morgenthaler JJ, Schubiger PA (1994) Internalization and degradation of monoclonal antibody chCE7 by human neuroblastoma cells. Int J Cancer 57: 427
26. Ong GL, Marria V, Mattes MJ (1994) The fate of antibodies and their radiolabels bound to tumor cells in vitro: the effect of cross-linking at the cell surface and of anti-idiotype antibodies. Cancer Immunol Immunother 39: 325
27. Pesando JM, Bouchard LS, McMaster BE (1989) CD19 is functionally and physically associated with surface immunoglobulin. J Exp Med 170: 2159
28. Pittman RC, Carew TE, Glass CK, Green SR, Taylor CA Jr, Attie AD (1983) A radioiodinated, intracellularly trapped ligand for determining the sites of plasma protein degradation in vivo. Biochem J 212: 791
29. Press OW, Hansen JA, Farr A, Martin PJ (1988) Endocytosis and degradation of murine anti-human CD3 monoclonal antibodies by normal and malignant T-lymphocytes. Cancer Res 48: 2249
30. Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ (1989) Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 49: 4906
31. Press OW, DeSantes K, Anderson SK, Geissler F (1990) Inhibition of catabolism of radiolabeled antibodies by tumor cells using lysosomotric amines and carboxylic ionophores. Cancer Res 50: 1243
32. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B, et al (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329: 1219
33. Press OW, Howell Clark J, Anderson S, Bernstein I (1994) Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 83: 1390
34. Ramakrishnan S, Houston LL (1984) Inhibition of human acute lymphoblastic leukemia cells by immunotoxins: potentiation by chloroquine. Science 223: 58
35. Rie MA de, Zeijlemaker WP, Borne AEGKr von dem (1988) Inhibition by vinca alkaloids and colchicine, of antigenic modulation induced by anti-CD 19 monoclonal antibodies. Leukemia Res 12: 135
36. Rinnooy Kan EA, Wright SD, Welte K, Wang CY (1986) Fc receptors on monocytes cause OKT3-treated lymphocytes to internalize T3 and to secrete IL-2. Cell Immunol 98: 181
37. Ruud E, Blomhoff HK, Funderud S, Godal T (1986) Imernalization and processing of antibodies to surface antigens on human B cells. Monoclonal anti-IgM antibodies are processed differently than monoclonal antibodies towards non-Ig surface receptors. Eur J Immunol 16: 286
38. Ryan DH (1992) Phenotypic heterogeneity in acute leukemia. Clin Chim Acta 206: 9
39. Schroff RW, Klein RA, Farrell MM, Stevenson HC (1984) Enhancing effects of monocytes on modulation of a lymphocyte membrane antigen. J Immunol 133: 2270
40. Sell C, Baserga R, Rubin R (1995) Insulin-like growth factor I (IGF-1) and the IGF-1 receptor prevent etoposide-induced apoptosis. Cancer Res 55: 303
41. Shih LB, Lu HH, Xuan H, Goldenberg DM (1994) Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int J Cancer 56: 538
42. Shih LB, Thorpe SR, Griffiths GL, Diril H, Ong GL, Hansen HJ, Goldenberg DM, Mattes MJ (1994) The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med 35: 899
43. Smith PJ, Soues S, Gottlieb T, Falk SJ, Watson JV, Osborne RJ, Bleehen NM (1994) Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells. Br J Cancer 70: 914
44. Tidefelt U, Juliusson G, Elmhorn Rosenborg A, Peterson C, Paul C (1994) Increased intracellular concentrations of doxorubicin in resistant lymphoma cells in vivo by concomitant therapy with verapamil and cyclosporin A. Eur J Haematol 52: 276
45. Uckun FM, Jaszcz W, Ambrus JL, Fauci AS, Gajl Peczalska K, Song CW, Wick MR, Myers DE, Waddick K, Ledbetter JA (1988) Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 71: 13
46. Vervoordeldonk SF, Merle PA, Van Leeuwen EF, Borne AEGKr von dem, Slaper-Cortenbach ICM (1994) Preclinical studies with radiolabeled B cell McAbs for treatment of patients with B cell malignancies. Cancer 73: 1006
47. Vervoordeldonk SF, Merle PA, Van Leeuwen EF, Van der School CE, Borne AEGKr von dem, Slaper-Cortenbach ICM (1994) Fey receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody. Blood 83: 1632
48. Wallace SL, Omokoku B, Ertel H (1970) Colchicine plasma levels - implications as to pharmacology and mechanism of action. Am J Med 48: 443
49. Zalutsky MR, Noska MA, Colapinto EV, Garg PK, Bigner DD (1989) Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate. Cancer Res 49: 5543